[1]吴铠悦,张丽允,冯文敏,等.基于网络药理学探讨西黄丸治疗肝癌的作用机制[J].福建医药杂志,2024,46(02):118-122.[doi:10.20148/j.fmj.2024.02.032]
点击复制

基于网络药理学探讨西黄丸治疗肝癌的作用机制()
分享到:

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年02期
页码:
118-122
栏目:
基础研究
出版日期:
2024-04-15

文章信息/Info

文章编号:
1002-2600(2024)02-0118-05
作者:
吴铠悦张丽允冯文敏黄月萍刘亚茹朱亚玲
华侨大学医学院,泉州 362021
关键词:
西黄丸 肝癌 网络药理学 分子对接
分类号:
R285.5; R735.7
DOI:
10.20148/j.fmj.2024.02.032
文献标志码:
B
摘要:
目的 运用网络药理学和分子对接技术探讨西黄丸治疗肝癌的潜在作用机制。方法 利用TCMSP、化学专业数据库及SwissTargetPrediction数据库获取西黄丸的活性成分及靶点; 从GeneCards、NCBI、DisGeNET及CTD数据库收集肝癌相关靶点,并与活性成分靶点取交集; 采用STRING平台和Cytoscape软件构建靶点相互作用网络,并借助DAVID数据库进行GO和KEGG富集分析; 利用CB-Dock分子对接工具将活性成分与关键靶点进行分子对接。结果 共筛选出205个活性成分和324个与肝癌治疗相关的潜在靶点,其中包括AR、CYP19A1、ESR1等61个关键靶点; GO和KEGG富集分析发现关键靶点参与凋亡过程的负调控、蛋白质磷酸化、细胞增殖的正调控等生物过程,调控HIF-1信号通路、PI3K-Akt信号通路、TNF信号通路等114条信号通路。分子对接结果显示没药甾醇I、洋椿苦素、白藜芦醇等活性成分与关键靶点之间均有较强的结合力。结论 西黄丸通过多成分、多靶点、多通路调控肝癌细胞的增殖、侵袭、迁移与凋亡,从而抑制肝癌的发生和发展。

参考文献/References:

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] GANESAN P,KULIK L M.Hepatocellular Carcinoma[J].Clinics in Liver Disease,2023,27(1):85-102.
[3] 王维德.外科证治全生集[M].北京:人民卫生出版社,2006:36.
[4] 周云娣.西黄丸辅助治疗晚期原发性肝癌效果观察[J].临床合理用药杂志,2020,13(4):73-75.
[5] WU J S,NIU Q,YUAN J,et al.Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1[J].Exp Ther Med,2019,18(6):4209-4220.
[6] ZHANG B C,YIN X N,SUI S G.Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3-kinase/protein kinase B pathway[J].Oncol Rep,2018,40(5):2758-2765.
[7] JIANG Y,QIAN Y,HONG H,et al.Morin protects chicks with T-2 toxin poisoning by decreasing heterophil extracellular traps,oxidative stress and inflammatory response[J].Br Poult Sci,2023,64(5):614-624.
[8] SIVARAMAKRISHNAN V,DEVARAJ S N.Morin fosters apoptosis in experimental hepatocellular carcinogenesis model[J].Chem Biol Interact,2010,183(2):284-292.
[9] MONTGOMERY E J,XING E,CAMPBELL M J,et al.Constitutively active androgen receptor in hepatocellular carcinoma[J].Int J Mol Sci,2022,23(22):13768.
[10] DAUKI A M,BLACHLY J S,KAUTTO E A,et al.Transcriptionally active androgen receptor splice variants promote hepatocellular carcinoma progression[J].Cancer Res,2020,80(3):561-575.
[11] COCCIADIFERRO L,MICELI V,GRANATA O M,et al.Merlin,the product of NF2 gene,is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells[J].J Steroid Biochem Mol Biol,2017,172:222-230.
[12] JEON Y,YOO J E,RHEE H,et al.YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior[J].Exp Mol Med,2021,53(6):1055-1067.
[13] MATSUSHIMA-NISHIWAKI R,YAMADA N,HATTORI Y,et al.SERMs(selective estrogen receptor modulator),acting as estrogen receptor β agonists in hepatocellular carcinoma cells,inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway[J].PLoS One,2022,17(1):e0262485.
[14] MOON H,RO S W.MAPK/ERK signaling pathway in hepatocellular carcinoma[J].Cancers(Basel),2021,3(12):3026-3045.
[15] HAO Y L,FANG H C,ZHAO H L,et al.The role of microRNA-1 targeting of MAPK3 in myocardial ischemia-reperfusion injury in rats undergoing sevoflurane preconditioning via the PI3K/Akt pathway[J].Am J Physiol Cell Physiol,2018,315(3):380-388.

相似文献/References:

[1]许扬梅 龚福生 刘沁颖 刘施佳 黄丽洁 郑秋红.MiR-194过表达和抑制表达对肝癌细胞株Hep-3b中侧群细胞增殖的影响[J].福建医药杂志,2019,41(06):141.
 XU Yangmei,GONG Fusheng,LIU Qinying,et al.Influence of miR-194 up and down-expression on liver cancer stem cells[J].FUJIAN MEDICAL JOURNAL,2019,41(02):141.
[2]黄雪平,王明霞,江丽凤,等.慢性乙型肝炎病毒感染患者血清sPD-1检测的临床意义[J].福建医药杂志,2022,44(03):8.
 HUANG Xueping,WANG Mingxia,JIANG Lifeng,et al.Detection and clinical significance of soluble programmed death factor-1 in patients with chronic viral hepatitis B[J].FUJIAN MEDICAL JOURNAL,2022,44(02):8.

备注/Memo

备注/Memo:
通信作者:朱亚玲,Email:zhuyaling@hqu.edu.cn
更新日期/Last Update: 2024-04-15